AVEO Oncology, an LG Chem company, Announces First Patient Dosed in Front-Line AML Combination Study of Ficlatuzumab
PR Newswire —
– Collaboration with Blood Cancer United® in its Beat AML® Master Clinical Trial – – AVEO's ficlatuzumab compound to be studied in combination with azacitidine and venetoclax in patients with AML in a Phase 1b/2 clinical trial – – First patient dosed into the Phase 1b/2 clinical trial –...